Post

New research · Neurology
BMJ open · 1d
Cross-sectionalBMJ open · 2026

Cross-sectional analysis of variation in diagnosis of Lewy body dementia in three English regions: data from the DETERMIND programme.

Calum A Hamilton, Alan J Thomas, Paul C Donaghy … Sube Banerjee
Read paper
NeurologyCross-sectional

Higher rates of Lewy body dementia diagnosis are associated with North East England.

Cross-sectional analysis of variation in diagnosis of Lewy body dementia in three English regions: data from the DETERMIND programme.

Calum A Hamilton et al. · BMJ open · 2026
Purpose

We aimed to examine regional differences in the relationship between core clinical features assessed using the Improving the DIAgnosis and Management Of Neurodegenerative Dementias of Lewy body type in the NHS (DIAMOND-Lewy) dementia with Lewy bodies (DLB) Assessment Toolkit and memory service diagnoses of Lewy body dementia (LBD).

Methods

935 individuals with a new memory service diagnosis of dementia enrolled in the DETERMinants of quality of life, care and costs, and consequences of INequalities in people with Dementia and their carers (DETERMIND) programme.

n = 935 individuals
Results

Risk of Lewy body dementia diagnosis was 1.72 times higher in North East England.

RR 1.72 (95% CI 1.35 to 2.08)
null 1
1.35
2.08
CI excludes the null - significant
More results

All core clinical features of DLB were associated with LBD diagnosis in North East England, whereas visual hallucinations were the most influential diagnostic feature in London and the South East (RR=3.18 (2.29-4.02)).

“
Conclusion · 1 of 2

Regional differences in LBD diagnosis in UK memory services appear to reflect different rates of recognition of specific LBD clinical features.

Conclusion · 2 of 2

Routinely using a standardised DLB Assessment Toolkit and improving awareness of non-hallucination features in LBD could help to address this disparity.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
17.8 years
Patients with congenital myasthenic syndromes waited 17.8 years for a diagnosis.
Guideline
“The introduction of the first anti-amyloid mAb represents a paradigm shift in the management of AD, but is not free of challenges.”
Study
more than 3.4 billion people
the global count of people living with brain and nerve conditions
Cohort Study
27.3%
the highest proportion of patients diagnosed with Charcot-Marie-Tooth disease type 1A
Study
95%
most specialized training program leaders were open to a unified date for job offers
Meta-analysis
RR 1.21
extended clot-busting treatment led to a 21% higher chance of excellent recovery from stroke
Study
over 80 cases
documented cases of brain and nerve conditions found in Inquisition records
Guideline
12-14 years
the age when patients with nerve and muscle conditions should start moving to adult care